Replies to post #1157 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Let's hope he is a straight shooter and is worthy of belonging to your alma mater.

If Tesneo is not launched, he should come out with a target price that would include approx. $40 million in revenue and an EPS of over $1. He can easily justify a target price if between $50 and $60.

If Tesneo is to be launched in January then when factoring the PPS, EPS should at least double and the one year target price should also double to between $100 and $120.

I expect Pryzbyl will conservatively under promise and over deliver. In addition ANIP will be providing guidance and a teleconference upon every quarterly earning report. If Prybyl remains conservative in his guidance, expect ANIP to regularly beat street estimates which will end up increasing target prices even further.

An co-promotion deal with Abbvie for Libigel, later this year if the CV patent has been secured, should give us a target price adjustment north of $300.

We could be in for a very tantalizing year if the above mention scenario plays itself out.